NO20080094L - Improved Crystalline Form of the Compound A-348441 - Google Patents
Improved Crystalline Form of the Compound A-348441Info
- Publication number
- NO20080094L NO20080094L NO20080094A NO20080094A NO20080094L NO 20080094 L NO20080094 L NO 20080094L NO 20080094 A NO20080094 A NO 20080094A NO 20080094 A NO20080094 A NO 20080094A NO 20080094 L NO20080094 L NO 20080094L
- Authority
- NO
- Norway
- Prior art keywords
- crystalline form
- compound
- improved crystalline
- ynylestra
- cholan
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 239000002178 crystalline material Substances 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- RPKLZQLYODPWTM-UHFFFAOYSA-N methyl 15-acetoxy(10),13E-ent-halimadien-18-oate Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RPKLZQLYODPWTM-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Polyesters Or Polycarbonates (AREA)
- Liquid Crystal Substances (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
Det beskrives et hemihydrat av (3ß, 5ß, 7a, 12a)-7,12-dihydroksy-3-{2-[{4-[17ß-hydroksy-3-okso-17a-prop-1-ynylestra-4,9-dien-11ß-yl]fenyl}(metyl)amino]etoksy}kolan-24-onsyre i en krystallinsk form som kjennetegnes ved et røntgendiffraksjonsmønster med hovedtopper ved 2? = 6,58 ± 0,2, 8,54 ± 0,2, 12,28 ± 0,2 og 19,68 ± 0,2. Dette krystallinske materiale er nyttig ved behandling av tilstander assosiert med et overskudd av hepatisk glukokortikoidrespons.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0514302.9A GB0514302D0 (en) | 2005-07-12 | 2005-07-12 | Improved crystalline material |
| PCT/EP2006/006811 WO2007006561A2 (en) | 2005-07-12 | 2006-07-12 | Improved crystalline form of the compound a-348441 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20080094L true NO20080094L (no) | 2008-03-26 |
Family
ID=34897118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20080094A NO20080094L (no) | 2005-07-12 | 2008-01-07 | Improved Crystalline Form of the Compound A-348441 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8124129B2 (no) |
| EP (1) | EP1910400B1 (no) |
| JP (1) | JP2009501175A (no) |
| CN (1) | CN101218246B (no) |
| AT (1) | ATE488525T1 (no) |
| AU (1) | AU2006268842B2 (no) |
| BR (1) | BRPI0612986A2 (no) |
| CA (1) | CA2614048A1 (no) |
| DE (1) | DE602006018318D1 (no) |
| DK (1) | DK1910400T3 (no) |
| ES (1) | ES2356255T3 (no) |
| GB (1) | GB0514302D0 (no) |
| IL (1) | IL188551A0 (no) |
| NO (1) | NO20080094L (no) |
| WO (1) | WO2007006561A2 (no) |
| ZA (1) | ZA200800278B (no) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100348609C (zh) * | 2002-06-19 | 2007-11-14 | 卡罗生物股份公司 | 治疗代谢紊乱的糖皮质激素受体配基 |
-
2005
- 2005-07-12 GB GBGB0514302.9A patent/GB0514302D0/en not_active Ceased
-
2006
- 2006-07-12 CA CA002614048A patent/CA2614048A1/en not_active Abandoned
- 2006-07-12 US US11/988,330 patent/US8124129B2/en not_active Expired - Fee Related
- 2006-07-12 BR BRPI0612986-2A patent/BRPI0612986A2/pt not_active IP Right Cessation
- 2006-07-12 WO PCT/EP2006/006811 patent/WO2007006561A2/en not_active Ceased
- 2006-07-12 AU AU2006268842A patent/AU2006268842B2/en not_active Expired - Fee Related
- 2006-07-12 DK DK06762551.7T patent/DK1910400T3/da active
- 2006-07-12 EP EP06762551A patent/EP1910400B1/en not_active Not-in-force
- 2006-07-12 JP JP2008520790A patent/JP2009501175A/ja active Pending
- 2006-07-12 DE DE602006018318T patent/DE602006018318D1/de active Active
- 2006-07-12 CN CN200680025210XA patent/CN101218246B/zh not_active Expired - Fee Related
- 2006-07-12 AT AT06762551T patent/ATE488525T1/de not_active IP Right Cessation
- 2006-07-12 ES ES06762551T patent/ES2356255T3/es active Active
-
2008
- 2008-01-02 IL IL188551A patent/IL188551A0/en unknown
- 2008-01-07 NO NO20080094A patent/NO20080094L/no not_active Application Discontinuation
- 2008-01-09 ZA ZA200800278A patent/ZA200800278B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200800278B (en) | 2009-03-25 |
| WO2007006561A3 (en) | 2007-04-12 |
| JP2009501175A (ja) | 2009-01-15 |
| CN101218246B (zh) | 2011-06-15 |
| IL188551A0 (en) | 2008-04-13 |
| US20090176754A1 (en) | 2009-07-09 |
| WO2007006561A2 (en) | 2007-01-18 |
| ATE488525T1 (de) | 2010-12-15 |
| CA2614048A1 (en) | 2007-01-18 |
| AU2006268842B2 (en) | 2012-02-23 |
| CN101218246A (zh) | 2008-07-09 |
| EP1910400A2 (en) | 2008-04-16 |
| DE602006018318D1 (de) | 2010-12-30 |
| US8124129B2 (en) | 2012-02-28 |
| DK1910400T3 (da) | 2011-02-28 |
| EP1910400B1 (en) | 2010-11-17 |
| BRPI0612986A2 (pt) | 2010-12-14 |
| ES2356255T3 (es) | 2011-04-06 |
| AU2006268842A1 (en) | 2007-01-18 |
| GB0514302D0 (en) | 2005-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081226A1 (es) | Polimorfo cristalino de 4-[5-[3-cloro-5-(trifluorometil)fenil]-4,5-dihidro-5-(trifluorometil)-3-isoxazolil]-n-[2-oxo-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenocarboxamida | |
| ZA200806460B (en) | Lightweight plasterboard and plaster slurry composition used for its manufacture | |
| DK1750688T3 (da) | Intraokulære steroidimplantater med udvidet længerevarende frisætning i en periode större end 2 måneder | |
| EP1938155A4 (en) | BUSINESS PROCESS EXECUTE ENGINE | |
| GB0524069D0 (en) | Preparation of templates for solid phase amplification | |
| DK1765290T3 (da) | Stabiliserede overmættede faste oplösninger af steroid-lægemidler | |
| BRPI0817096A8 (pt) | Análogo de tiazolidinodiona e composição farmacêutica que o compreende | |
| EP1719768A4 (en) | NEW COMPOUNDS OF BENZOTHIAZ PINE AND BENZOTHI PINE | |
| UA83720C2 (ru) | Кристаллическая форма v агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит | |
| EP2057139A4 (en) | Sulfuric acid derivatives of non-steroidal anti-inflammatory drugs | |
| EA200802385A1 (ru) | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 11β-(4-АЦЕТИЛФЕНИЛ)-20,20,21,21,21-ПЕНТАФТОР-17-ГИДРОКСИ-19-НОР-17A-ПРЕГНА-4,9-ДИЕН-3-ОНА | |
| DE602005001821D1 (de) | Elektronisches Steuerungssystem für die Starterklappe eines Vergasers | |
| PT2426209E (pt) | Oxidorredutases para a redução estereosseletiva decompostos ceto | |
| GB0325215D0 (en) | Design of vanes for exposure to vibratory loading | |
| NO20074623L (no) | Fremgangsmate for peptidsyntese | |
| TWI367983B (en) | Draghead for a trailing suction hopper and process for dredging by means of this draghead | |
| DK1910400T3 (da) | Forbedret krystallinsk form af forbindelsen A-348441 | |
| EP1813987A4 (en) | COMPOSITION CONTAINING A SULFONIC ESTER FOR THE FORMATION OF ANTIREFLECTION FILM FOR LITHOGRAPHY | |
| EP1726992A4 (en) | NEGATIVE RESIST COMPOSITION | |
| EP1752464A4 (en) | PROCESS FOR THE PREPARATION OF TIMOSAPONIN B II | |
| EP1811342A4 (en) | SCHWEFELATOME CONTAINING COMPOUND FOR GENERATING A LITHOGRAPHIC ANTIREFLEX FILM | |
| ATE303397T1 (de) | 9-alpha-substituierte estratriene als selektiv wirksame estrogene | |
| FR2897863B1 (fr) | Procede d'hydrofugation d'un produit a base de gypse forme a partir d'une composition a base de platre | |
| ECSP099344A (es) | Modificaciones de cristal de la 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-pirrol-2,5-diona | |
| ITMI20051970A1 (it) | Processo per la preparazione di eteri misti derivanti dall'inaftolo e intermedi di forme cristalline definite di + e - duloxetina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |